1. Oakley, P, Kisely, S, Baxter, A, et al. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. J Psychiatr Res 2018; 102: 245–253.
Google Scholar | Crossref | Medline2. Lawrence, D, Hancock, KJ, Kisely, S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013; 346: f2539.
Google Scholar | Crossref3. Pillinger, T, Beck, K, Gobjila, C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 2017; 74: 261–269.
Google Scholar | Crossref | Medline | ISI4. Firth, J, Siddiqi, N, Koyanagi, A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019; 6: 675–712.
Google Scholar | Crossref | Medline5. Stubbs, B, Firth, J, Berry, A, et al. How much physical activity do people with schizophrenia engage in? a systematic review, comparative meta-analysis and meta-regression. Schizophr Res 2016; 176: 431–440.
Google Scholar | Crossref | Medline6. Mitchell, AJ, Vancampfort, D, Sweers, K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull 2013; 39: 306–318.
Google Scholar | Crossref | Medline | ISI7. Siskind, D, Orr, S, Sinha, S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. Epub ahead of print 11 May 2021. DOI: 10.1192/bjp.2021.61.
Google Scholar | Crossref8. Howes, OD, McCutcheon, R, Agid, O, et al. Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216–229.
Google Scholar | Crossref | Medline | ISI9. Siskind, D, McCartney, L, Goldschlager, R, et al. Clozapine v. First-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–392.
Google Scholar | Crossref | Medline | ISI10. Land, R, Siskind, D, McArdle, P, et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 2017; 135: 296–309.
Google Scholar | Crossref | Medline11. Vermeulen, JM, van Rooijen, G, van de Kerkhof, MP, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull 2019; 45: 315–329.
Google Scholar | Crossref | Medline12. Siskind, D, Harris, M, Phillipou, A, et al. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci 2017; 26: 325–337.
Google Scholar | Crossref | Medline13. Siskind, D, Kisely, S. Balancing body and mind: selecting the optimal antipsychotic. Lancet 2019; 394: 900–902.
Google Scholar | Crossref | Medline14. Rosenbaum, S, Tiedemann, A, Sherrington, C, et al. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2014; 75: 964–974.
Google Scholar | Crossref | Medline | ISI15. Strassnig, M, Caceda, R, Newcomer, J, et al. Cognitive deficits, obesity and disability in schizophrenia. Translat Neurosci 2012; 3: 345–354.
Google Scholar | Crossref16. Roerig, JL, Steffen, KJ, Mitchell, JE. Atypical antipsychotic-induced weight gain. CNS Drugs 2011; 25: 1035–1059.
Google Scholar | Crossref | Medline | ISI17. Suetani, RJ, Siskind, D, Reichhold, H, et al. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Psychopharmacology 2017; 234: 2989–3008.
Google Scholar | Crossref | Medline18. Mayfield, K, Siskind, D, Winckel, K, et al. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. J Psychopharmacol 2016; 30: 227–236.
Google Scholar | SAGE Journals | ISI19. Coll, AP, Chen, M, Taskar, P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2020; 578: 444–448.
Google Scholar | Crossref | Medline20. Siskind, DJ, Leung, J, Russell, AW, et al. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One 2016; 11: e0156208.
Google Scholar | Crossref | Medline21. Spokes, J, Hollingworth, S, Winckel, K, et al. Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study. Ther Adv Psychopharmacol 2021; 11.
Google Scholar | SAGE Journals22. Cooper, SJ, Reynolds, GP, Barnes, T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30: 717–748.
Google Scholar | SAGE Journals | ISI23. Siskind, D, Friend, N, Russell, A, et al. CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ Open 2018; 8: e021000.
Google Scholar | Crossref24. Therapeutic Goods Administration . Product information apo metformin XR product and consumer medicine information, https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01440-1 (accessed 7 September 2021).
Google Scholar25. Desilets, AR, Dhakal-Karki, S, Dunican, KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008; 42: 817–826.
Google Scholar | SAGE Journals | ISI26. Levine, J, Schooler, N. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22: 343–381.
Google Scholar | Medline27. World Health Organization . Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008, 2011, https://www.who.int/publications/i/item/9789241501491.
Google Scholar28. Pickering, TG, Hall, JE, Appel, LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Circulation 2005; 111: 697–716.
Google Scholar | Crossref | Medline | ISI29. Dyson, JK, Anstee, QM, McPherson, S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014; 5: 211–218.
Google Scholar | Crossref | Medline30. Sterling, RK, Lissen, E, Clumeck, N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–1325.
Google Scholar | Crossref | Medline | ISI31. White, MA, Whisenhunt, BL, Williamson, DA, et al. Development and validation of the food-craving inventory. Obes Res 2002; 10: 107–114.
Google Scholar | Crossref | Medline32. Kay, SR, Fiszbein, A, Opfer, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–276.
Google Scholar | Crossref | Medline | ISI33. Jones, SH, Thornicroft, G, Coffey, M, et al. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654–659.
Google Scholar | Crossref | Medline | ISI34. Spitz, AF, Kanani, H. Change in HbA1c as a measure of quality of diabetes care. Diabetes Care 2006; 29: 1184–1185.
Google Scholar | Crossref35. Ting, RZ-W, Szeto, CC, Chan, MH-M, et al. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006; 166: 1975–1979.
Google Scholar | Crossref | Medline36. Williamson, DA, Bray, GA, Ryan, DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity 2015; 23: 2319–2320.
Google Scholar | Crossref | Medline37. Wu, R-R, Zhao, J-P, Guo, X-F, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165: 352–358.
Google Scholar | Crossref | Medline | ISI38. Baptista, T, Martínez, J, Lacruz, A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006; 51: 192–196.
Google Scholar | SAGE Journals | ISI39. Faulkner, G, Cohn, T, Remington, G, et al. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res 2007; 90: 174–178.
Google Scholar | Crossref | Medline | ISI40. Young, SJ, Praskova, A, Hayward, N, et al. Attending to physical health in mental health services in Australia: a qualitative study of service users’ experiences and expectations. Health Soc Care Community 2017; 25: 602–611.
Google Scholar | Crossref | Medline41. Global BMI Mortality Collaboration , Di Angelantonio, E, Bhupathiraju, S, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016; 388: 776–786.
Google Scholar | Crossref | Medline42. Flegal, KM, Kit, BK, Orpana, H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309: 71–82.
Google Scholar | Crossref | Medline | ISI43. McWhinney, S, Kolenic, M, Franke, K, et al. Obesity as a risk factor for accelerated brain ageing in first-episode psychosis – a longitudinal study. Schizophr Bull. Epub ahead of print 3 June 2021. DOI: 10.1093/schbul/sbab064.
Google Scholar | Crossref44. Angulo, P. Obesity and nonalcoholic fatty liver disease. Nutr Rev 2007; 65(Suppl. 1): S57–S63.
Google Scholar | Crossref | Medline45. Byrne, CD, Targher, G. NAFLD: a multisystem disease. J Hepatol 2015; 62: S47–S64.
Google Scholar | Crossref